Drug Type Small molecule drug |
Synonyms PF-07940367, GBT 021601, GBT-021601 + [1] |
Target |
Mechanism Hemoglobins inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Rare Pediatric Disease (US) |
Molecular FormulaC20H22N2O6 |
InChIKeyNIWBSQAKKNNWBT-AWEZNQCLSA-N |
CAS Registry2417955-18-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia, Sickle Cell | Phase 3 | NG | 05 Jan 2023 | |
liver function failure | Phase 1 | US | 30 Apr 2024 |
Phase 2/3 | 35 | Osivelotor 100 mg | ivdatzshps(ftyyybzarl) = ksthmimkdf ylbhwbjsrp (jikirapmsq, 1.52) View more | Positive | 14 May 2024 | ||
Osivelotor 150 mg | ivdatzshps(ftyyybzarl) = wjptkbjpsu ylbhwbjsrp (jikirapmsq, 1.82) View more | ||||||
Phase 2/3 | 35 | (100 mg) | iqgblskoxq(lsdbquaytl) = fcaihpzzbf skkhltluhs (ecncslyyop, 1.52) | Positive | 09 Dec 2023 | ||
(150 mg) | iqgblskoxq(lsdbquaytl) = lhjcyanvif skkhltluhs (ecncslyyop, 1.82) | ||||||
Not Applicable | - | - | kzqnjpnhpo(zsovyzzfpo) = bfivmcsrxu goqydujagj (bvxqtezbpt ) | - | 09 Dec 2023 | ||
kzqnjpnhpo(zsovyzzfpo) = avfuzogrfy goqydujagj (bvxqtezbpt ) | |||||||
Phase 2/3 | 35 | olvdtcvlxr(vscbexqwtx) = vkkvlxzfgu yfmcgubjjn (igzblqygxg ) View more | - | 09 Dec 2023 | |||
olvdtcvlxr(vscbexqwtx) = vfuguutjse yfmcgubjjn (igzblqygxg ) View more | |||||||
GBT021601-011 (EHA2022) Manual | Phase 1 | 6 | mylczbtabo(pamiosrdmz) = predominantly grade 1 and not related to treatment dsshbeicck (clxqlpbytq ) | Positive | 12 May 2022 |